Logo and Schema therapy

Objective: <span class="fontstyle2">This study aimed at evaluating the effectiveness of mindfulness-based cognitive therapy, logo therapy, and schema therapy on reducing stress, anxiety, and depression in patients with multiple sclerosis. Methods: <span class="fontstyle2">The present study was a quasi-experimental study with a pre-test-post-test design with a control group. The study population consisted of all members of the MS Society of Iran located in Tehran in 2019, and the sample consisted of 60 members of the Association who were selected using the convenience sampling method and were randomly assigned to three experimental groups and one control group (15 people for each group). All four groups were tested by DASS-21 scale, and then the experimental groups underwent mindfulness-based cognitive therapy, logo therapy, and schema therapy in 12 Two-hour sessions for 12 weeks, but the control group did not receive any training. Analysis was performed using SPSS22 in two parts: descriptive and inferential statistics. Results: <span class="fontstyle2">The results of analysis showed that mindfulness-based cognitive therapy has been effective on reducing stress (f= 110.90, p <0,001), anxiety (f= 88.92, p <0,001), and depression (f= 32.29, p <0,001) in patients with multiple sclerosis. Also it was shown that logo therapy was effective on stress (f= 264.60, p <0,001), anxiety (f= 175, p <0,001), and depression (f= 305.07, p <0,001), and schema therapy was effective on reducing stress (f=110.90, p <0,001), anxiety (f= 88.92, p <0,001), and depression (f= 32.29, p <0,001) in patients with multiple sclerosis. Also, the comparison of means showed that in the variables of stress, anxiety, and depression, mindfulness-based cognitive therapy, logo therapy, and schema therapy were effective. Conclusions: <span class="fontstyle2">The findings of this study confirmed that mindfulness-based cognitive therapy, logo therapy, and schema therapy were effective in reducing stress, anxiety, and depression in patients with multiple sclerosis.